secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2026-05-13T20:05:34+00:00
Accession:  0001193125-26-221596
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q1 revenue $12.1M (+43% YoY); guides FY2026 $52-56M
--------------------------------------------------------------------

- Record Q1 revenue of $12.1M; organic device growth 25% YoY; gross margin expanded to 64% from 60%.
- Neurosurgery navigation revenue surged 80% to $5.9M, driven by IRRA flow and 3.0 software adoption.
- Biologics & drug delivery revenue stable at $4.8M; over 60 active biopharma partners enrolled.
- Cash and equivalents $35.6M at Mar 31, 2026; expects cash burn to reduce in H2 2026 from cost synergies.
- FDA cleared Velocity Alpha drill used in first clinical procedure; Health Canada MDL license obtained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000119312526221596/0001193125-26-221596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000119312526221596/clpt-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-221596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer